Life Sciences market research reports by Global Markets Direct

• Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Dec 28, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipelin ... Read More

• Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipelin ... Read More

• Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report, Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitut ... Read More

• Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Drugs In Development, 2022, provides an overview of the Multiple Sclerosis ... Read More

• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy (MSA or S ... Read More

• Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ... Read More

• Wounds Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Wounds Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Drugs In Development, 2022, provides an overview of the Wounds (Dermatology) pipeline landscape. Wo ... Read More

• Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report, Alpha Synuclein (Non A Beta Component Of AD A ... Read More

• Myocardial Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Myocardial Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Drugs In Development, 2022, provides an overview of the Myocardial Fibros ... Read More

• Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Drugs In Development, 2022, provides an overview of the Macular Edema (Ophthalmology) ... Read More

• Canavan Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Canavan Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Drugs In Development, 2022, provides an overview of the Canavan Disease (Central ... Read More

• Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2022, provides ... Read More

• Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Drugs In Development, 2022, provides an ove ... Read More

• Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides an overview of ... Read More

• Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Drugs In Dev ... Read More

• Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Drugs In Developm ... Read More

• Pertussis (Whooping Cough) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Pertussis (Whooping Cough) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Drugs In Development, 2022, provides an overview of the Per ... Read More

• Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 mole ... Read More

• Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Drugs In Development, 2022, provides an overview of the Huntington Disease ... Read More

• Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Drugs In Development, 2022, provides an overview of the Myelody ... Read More

• Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Drugs In Development, 2022, provides an overview of the Wilson Disease (Genetic Dis ... Read More

• Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It ... Read More

• Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Drugs In Development, 2022, provides an overview of the Sicca S ... Read More

• Radiodermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Radiodermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Drugs In Development, 2022, provides an overview of the Radiodermatitis (Toxicolo ... Read More

• Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ornithine-Transcarbamylase Deficiency - Drugs In Development, 2022, provides ... Read More

< prev 1 2 3 4 5 6 7 8 9 10 next >